Lead Product(s) : Cannabidiol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Can-Fite BioPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Details : DehydraTECH-CBD (cannabidiol) is a DehydraTECH-processed CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of diabetes and weight loss.
Product Name : DehydraTECH-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Can-Fite BioPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Product Name : CMND-100
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 28, 2023
Lead Product(s) : 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Aegis Capital
Deal Size : $2.2 million
Deal Type : Public Offering
Clearmind Medicine Closes US$2.25 Million Public Offering
Details : The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Product Name : CMND-100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Aegis Capital
Deal Size : $2.2 million
Deal Type : Public Offering
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Aegis Capital
Deal Size : $2.2 million
Deal Type : Public Offering
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
Details : The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Product Name : CMND-100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Aegis Capital
Deal Size : $2.2 million
Deal Type : Public Offering
Lead Product(s) : 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Hebrew University of Jerusalem
Deal Size : Undisclosed
Deal Type : Agreement
Details : The collaboration aims to evaluate Clearmind's and SciSparc's combination treatment of MEAI (5-methoxy-2-aminoindane), a novel proprietary psychedelic treatment, and PEA (phenethylamine), the active ingredient of CannAmide, for obesity and metabolic synd...
Product Name : CMND-100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 16, 2023
Lead Product(s) : 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Hebrew University of Jerusalem
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The animals treated with MEAI (5-methoxy-2-aminoindane) showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being ...
Product Name : CMND-100
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 5-Methoxy-2-Aminoindane,Cannamide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMND-100 (5-methoxy-2-aminoindane), which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global un...
Product Name : CMND-100
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : 5-Methoxy-2-Aminoindane,Cannamide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Paraza Pharma
Deal Size : Undisclosed
Deal Type : Partnership
NIMIUM and Paraza Pharma form Partnership to Treat Cardiometabolic Disease
Details : The partnership will focus on the early-stage development of glycerol-3-phosphate phosphatase (G3PP) activators.The treatment aims to prevent and reverse the adverse effects of excess sugar and caloric intake and to promote healthier aging.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Paraza Pharma
Deal Size : Undisclosed
Deal Type : Partnership